Feelnor MR 35 mg Tablet contains Trimetazidine, a metabolic anti-ischemic agent used as add-on therapy in the management of stable angina pectoris. It is specifically prescribed for adult patients whose angina symptoms are not adequately controlled by, or who are intolerant to, first-line anti-anginal therapies such as beta-blockers, calcium channel blockers, or nitrates. Feelnor MR works at the cellular metabolic level to improve cardiac efficiency without affecting heart rate or blood pressure.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Other Anti-anginal & Anti-ischaemic Drugs

Indications

Feelnor MR 35 mg is indicated in adults as add-on therapy for the symptomatic treatment of stable angina pectoris, particularly in patients who remain symptomatic despite standard anti-anginal treatment or cannot tolerate first-line therapies.

Pharmacology

Trimetazidine is a 3-keto acyl-CoA thiolase (KAT) inhibitor, making it a unique metabolic anti-ischemic agent. It works by partially inhibiting fatty acid oxidation in cardiac cells and shifting energy production toward glucose oxidation. Since glucose metabolism requires less oxygen to generate the same amount of energy, this metabolic shift improves myocardial efficiency under ischemic conditions. Additionally, enhanced glucose oxidation reduces lactic acid accumulation, helping to prevent angina-related chest pain and improve exercise tolerance.

Mode of Action

Feelnor MR 35 mg inhibits the fatty acid metabolic pathway by blocking the 3-keto acyl-CoA thiolase enzyme. This promotes glucose oxidation, which is a more oxygen-efficient energy pathway. As a result, the heart produces more energy from the same oxygen supply, improving myocardial function and reducing ischemia-related symptoms such as angina pectoris.

Dosage & Administration

• Recommended dose: Trimetazidine 35 mg twice daily during meals

• Alternatively, 20 mg three times daily may be used

• Treatment response should be evaluated after three months

• Discontinue therapy if no clinical benefit is observed

Dosage adjustment may be required in patients with renal impairment.

Drug Interactions

No clinically significant drug interactions have been reported. Trimetazidine has been safely used alongside beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents, and digitalis preparations.

Contraindications

Feelnor MR 35 mg is contraindicated in patients with:

• Hypersensitivity to Trimetazidine or any excipients

• Parkinson’s disease or parkinsonian symptoms

• Tremors or restless legs syndrome

• Severe renal impairment

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Trimetazidine is generally safe and well tolerated. Common side effects may include:

• Dizziness and headache

• Abdominal pain, diarrhoea, dyspepsia

• Nausea and vomiting

• Skin reactions such as rash, pruritus, urticaria

• Asthenia

Most adverse effects are mild and reversible.

Pregnancy & Lactation

There is limited data on the use of Trimetazidine in pregnant women. Animal studies do not indicate reproductive toxicity, but as a precaution, its use during pregnancy is not recommended. It is unknown whether Trimetazidine is excreted in human milk; therefore, it should not be used during breastfeeding due to potential risk to the infant.

Precautions & Warnings

Feelnor MR 35 mg is not intended for acute angina attacks, unstable angina, or myocardial infarction. It should only be used as supportive therapy for stable angina under medical supervision.

Storage Conditions

Store in a dry place away from light and heat. Keep out of the reach of children.